Investig Clin Urol.  2017 Jul;58(4):220-227. 10.4111/icu.2017.58.4.220.

Novel immunotherapy in metastatic renal cell carcinoma

• Cho YH
• Kim MS
• Chung HS
• Hwang EC

• KMID: 2410287
• DOI: http://doi.org/10.4111/icu.2017.58.4.220

Abstract

Despite the rapid development of therapeutic modalities for metastatic renal cell carcinoma (mRCC) over the past decade to include a number of targeted antiangiogenic therapies and traditional immunotherapy, such as high-dose interleukin-2 and interferon-α, mRCC continues to be associated with poor prognosis. Currently, several novel immunotherapy agents, such as cancer vaccines, adoptive cell therapy, and checkpoint inhibitors, such as programmed cell death-1 (PD-1 present on T cells), one of its ligands (PD-L1 present on antigen-presenting cells and tumor cells), and cytotoxic T-lymphocyte-associated protein-4 pathways, are being studied in mRCC and are showing promise as important steps in the management of this disease. This review summarizes the current landscape of standard and emerging immune therapeutics and other modalities for mRCC.

Keyword

Immune checkpoint inhibitors; Immunotherapy; Renal cell carcinoma; Vaccines

MeSH Terms

Antigen-Presenting Cells
Cancer Vaccines
Carcinoma, Renal Cell*
Cell- and Tissue-Based Therapy
Immunotherapy*
Interleukin-2
Ligands
Prognosis
Vaccines
Cancer Vaccines
Interleukin-2
Ligands
Vaccines

Reference

1. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian cancer statistics 2015. Toronto (ON): Canadian Cancer Society;2015.

2. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al. Corrigendum to “The epidemiology of renal cell carcinoma” [Eur Urol 2011;60:615-21]. Eur Urol. 2011; 60:1317. PMID: 27989534.

3. Athar U, Gentile TC. Treatment options for metastatic renal cell carcinoma: a review. Can J Urol. 2008; 15:3954–3966. PMID: 18405442.

4. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008; 34:193–205. PMID: 18313224.

5. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316:889–897. PMID: 3493432.

6. Escudier B, Goupil MG, Massard C, Fizazi K. Sequential therapy in renal cell carcinoma. Cancer. 2009; 115(10 Suppl):2321–2326. PMID: 19402067.

7. Sun M, Lughezzani G, Perrotte P, Karakiewicz PI. Treatment of metastatic renal cell carcinoma. Nat Rev Urol. 2010; 7:327–338. PMID: 20458330.

8. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 2011; 16(Suppl 2):14–22. PMID: 21346036.

9. Decker WK, Safdar A. Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine Growth Factor Rev. 2009; 20:271–281. PMID: 19656718.

10. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39:1–10. PMID: 23890059.

11. Oliver RT, Nethersell AB, Bottomley JM. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989; 63:128–131. PMID: 2702395.

12. Fosså SD. Interferon in metastatic renal cell carcinoma. Semin Oncol. 2000; 27:187–193. PMID: 10768597.

13. Floros T, Tarhini AA. Anticancer cytokines: biology and clinical effects of interferon-α2, interleukin (IL)-2, IL-15, IL-21, and IL-12. Semin Oncol. 2015; 42:539–548. PMID: 26320059.

14. Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S. Trial watch: therapeutic vaccines in metastatic renal cell carcinoma. Oncoimmunology. 2015; 4:e1001236. PMID: 26155388.

15. Figlin RA. Personalized immunotherapy (AGS-003 ) when combined with sunitinib for the treatment of metastatic renal cell carcinoma. Expert Opin Biol Ther. 2015; 15:1241–1248. PMID: 26125651.

16. Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ, et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015; 3:14. PMID: 25901286.

17. Bedke J, Stenzl A. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now? Expert Rev Anticancer Ther. 2013; 13:1399–1408. PMID: 24215158.

18. Pal SK, Hu A, Figlin RA. A new age for vaccine therapy in renal cell carcinoma. Cancer J. 2013; 19:365–370. PMID: 23867519.

19. ClinicalTrials.gov. Phase 3 trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma (RCC). ClinicalTrials.gov Identifier: NCT01582672 [Internet]. Bethesda (MD): U.S. National Library of Medicine;U.S. National Institutes of Health;U.S. Department of Health and Human Services;c2017. cited 2017 Mar 2. Available from: https://clinicaltrials.gov/ct2/show/NCT01582672.

20. Bedke J, Stenzl A. IMA901: a peptide vaccine in renal cell carcinoma. Expert Opin Investig Drugs. 2013; 22:1329–1336.

21. Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multipeptide cancer vaccine for treatment of renal cell cancer. Hum Vaccin Immunother. 2014; 10:3179–3189. PMID: 25625928.

22. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18:1254–1261. PMID: 22842478.

23. Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008; 14:6674–6682. PMID: 18927310.

24. Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S, et al. IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2016; 17:1599–1611. PMID: 27720136.

25. Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol Ther. 2010; 10:281–287. PMID: 20088718.

26. Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother. 2009; 32:765–772. PMID: 19561532.

27. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009; 7:2. PMID: 19128501.

28. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010; 16:5539–5547. PMID: 20881001.

29. Wittke S, Baxmann S, Fahlenkamp D, Kiessig ST. Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine. Onco Targets Ther. 2016; 9:523–537. PMID: 26889089.

30. Matsushita H, Enomoto Y, Kume H, Nakagawa T, Fukuhara H, Suzuki M, et al. A pilot study of autologous tumor lysate-loaded dendritic cell vaccination combined with sunitinib for metastatic renal cell carcinoma. J Immunother Cancer. 2014; 2:30. PMID: 25694811.

31. Wang H, Feng F, Zhu M, Wang R, Wang X, Wu Y, et al. Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015; 31:67–71. PMID: 25575061.

32. May M, Kendel F, Hoschke B, Gilfrich C, Kiessig S, Pflanz S, et al. Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years. Urologe A. 2009; 48:1075–1083. PMID: 19562320.

33. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985; 313:1485–1492. PMID: 3903508.

34. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993; 85:622–632. PMID: 8468720.

35. Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, et al. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urol. 1998; 5:16–21. PMID: 9535595.

36. Wersäll P, Mellstedt H. Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN. Med Oncol. 1995; 12:69–77. PMID: 8535664.

37. Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Shuman WP, et al. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells. Cancer Res. 1989; 49:235–240. PMID: 2783243.

38. Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015; 6:e0004. PMID: 25717386.

39. Tang X, Liu T, Zang X, Liu H, Wang D, Chen H, et al. Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis. PLoS One. 2013; 8:e62847. PMID: 23667530.

40. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12:252–264. PMID: 22437870.

41. Webster RM. The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov. 2014; 13:883–884. PMID: 25345674.

42. Byun DJ, Wolchok JD, Rosenberg LM, Girotra M. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol. 2017; 13:195–207. PMID: 28106152.

43. Ghatalia P, Zibelman M, Geynisman DM, Plimack ER. Checkpoint inhibitors for the treatment of renal cell carcinoma. Curr Treat Options Oncol. 2017; 18:7. PMID: 28210995.

44. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011; 17:6958–6962. PMID: 21900389.

45. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711–723. PMID: 20525992.

46. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007; 30:825–830. PMID: 18049334.

47. Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2015; 7:365–377. PMID: 26622321.

48. Tykodi SS. PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther. 2014; 7:1349–1359. PMID: 25114573.

49. Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006; 66:3381–3385. PMID: 16585157.

50. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A. 2004; 101:17174–17179. PMID: 15569934.

51. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366:2443–2454. PMID: 22658127.

52. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015; 33:1430–1437. PMID: 25452452.

53. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1803–1813. PMID: 26406148.

54. Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med. 2014; 18:341–350. PMID: 25549705.

55. Gunturi A, McDermott DF. Potential of new therapies like anti-PD1 in kidney cancer. Curr Treat Options Oncol. 2014; 15:137–146. PMID: 24504486.

56. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016; 34:833–842. PMID: 26755520.

57. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366:2455–2465. PMID: 22658128.

58. Pal SK, Vogelzang NJ. Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma. Clin Adv Hematol Oncol. 2013; 11:146–155. PMID: 23598982.

59. Buonerba C, Di Lorenzo G, Sonpavde G. Combination therapy for metastatic renal cell carcinoma. Ann Transl Med. 2016; 4:100. PMID: 27047959.

60. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358:966–970. PMID: 11583750.

61. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004; 171:1071–1076. PMID: 14767273.

62. Aslam MZ, Matthews PN. Cytoreductive nephrectomy for metastatic renal cell carcinoma: a review of the historical literature and its role in the era of targeted molecular therapy. ISRN Urol. 2014; 2014:717295. PMID: 24587921.